AstraZeneca Pharma India Limited has informed regarding Disclosure of material issue under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Regulatory & Legal View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹9083.50

prior close

₹9013.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-0.7% vs market

Pharmaceuticals peers, median of 152sector-0.0%-0.8% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.1-0.7-0.0-0.8

Next day

-1.0+0.7-1.6-0.2-0.8

-0.8+1.2-2.0+0.1-0.9

+0.2+1.9-1.7+0.0+0.2

+0.1+1.6-1.6+0.4-0.3

-1.4+2.0-3.4+0.1-1.5

-3.5+0.9-4.5-0.6-2.9

15d

+3.2-1.4+4.7-3.0+6.3

+1.5-1.6+3.1-3.7+5.2

+2.0-0.7+2.7-4.3+6.4

+0.8-6.0+6.7-7.5+8.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India has submitted a material disclosure to the stock exchanges under SEBI's Listing Obligations and Disclosure Requirements (Regulation 30). The full details of the material issue were not included in the headline provided. Reg 30 disclosures cover events that could have a significant impact on the company's operations, financials, or stock price, such as regulatory actions, litigation, or major business changes. Shareholders should refer to the detailed filing or the company's official communication for specifics on what was disclosed.

Likely market impact

The nature of the material issue is unclear from the available information, so the exact impact on shareholders or the stock cannot be determined. Investors should review the full disclosure document for clarity on any potential risks or developments.